Alimera Sciences to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference
Alimera Sciences, a pharmaceutical firm focusing on ophthalmology, announced that President and CEO Rick Eiswirth will present at the Inaugural Emerging Growth Virtual Conference on March 17-18, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alimera Sciences, a pharmaceutical firm focusing on ophthalmology, announced that President and CEO Rick Eiswirth will present at the Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. Investors can view his presentation on March 17 after registering for the conference. An archived replay will also be accessible on the conference website. Alimera is dedicated to addressing retinal diseases, which often lack effective treatments and significantly impact aging populations. For more information, visit www.alimerasciences.com.
Details
News Market Reaction – ALIM
The recorded move for ALIM in the trading session of this news was +22.44%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ATLANTA, March 11, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at Maxim Group’s Inaugural Emerging Growth Virtual Conference to be held March 17-18, 2021.
Investors can view Mr. Eiswirth’s general corporate presentation on March 17 once they register for the conference here, and an archived replay of the presentation will be available via the conference website. Investors can also request a 1x1 meeting with Mr. Eiswirth to be arranged following the conclusion of the conference.
About Alimera Sciences, Inc.
Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.
| For press inquiries: Jules Abraham for Alimera Sciences 917-885-7378 julesa@coreir.com | For investor inquiries: Scott Gordon for Alimera Sciences scottg@coreir.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.